Brain Metastasis Therapeutics Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026

Brain metastasis is a type of cancer that usually occurs due to the spread of cancerous cells to brain. Thus, it is also known as metastatic brain tumor or secondary brain cancer, while in primary brain cancer the tumor occurs in the brain. Brain metastasis is common as compared to the primary brain cancer. Brain metastasis is a major complication of systemic cancer and is one of the major reasons causing morbidity and mortality in cancer patients. The common type of cancer that spread to the brain are breast cancer, lung cancer, melanoma, renal cell carcinoma and colon. The cancer may spread to any part of brain but it is commonly found in the brain cerebrum. Cerebellum and stem cells are rarely found to be affected by brain metastasis. Brain metastasis may be single tumor or multiple, although multiple brain metastasis is common. The symptoms associated with brain metastasis are edema, seizure and severe headache. Therefore the first line of treatment for brain metastasis is treating the symptoms.

Brain Metastasis Therapeutics Market: Drivers & Restraints

The global brain metastasis therapeutics market is driven by the increasing need of treatment for symptoms associated with brain metastasis. Also, the chemotherapeutic agents are known to be the primary tools for cancer treatment which are estimated to increase the overall brain metastasis therapeutic market. The increased prevalence of cancer that spread to the brain are also expected to drive the global metastasis therapeutics market. Though the market seems to be opportunistic in the forecast period there are some factors such as high cost of treatment and side effects associated with the chemotherapy are expected to restrain the growth of brain metastasis therapeutics market.

Request free sample Report:

Brain Metastasis Therapeutics Market: Segmentation

Brain metastasis therapeutics market is segmented on the basis of treatment...